ReviewInternational journal of molecular sciences2025
High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association Between Monocyte-to-High-Density Lipoprotein Ratio and Diabetic Nephropathy: A Systematic Review and Meta-Analysis.BioMed research international · 2026Pooled it
- Association between serum lipid levels and the risk of diabetic nephropathy: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Relationship between apolipoprotein A levels and chronic kidney disease stage 4-5 in Chinese type 2 diabetes participants.International urology and nephrology · 2026Article
- Lipid metabolic dysregulation in diabetic kidney disease: mechanisms, cellular impact, and therapeutic strategies.Journal of clinical & translational endocrinology · 2026Review
- Metabolomic etiological insights into six diabetic complications: a large scale Mendelian randomization atlas with colocalization validation.Acta diabetologica · 2026Article
- Development of a machine learning-based early prediction model for disease severity in acute pancreatitis.European journal of medical research · 2026Article
- J-shaped association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and heart failure: a cross-sectional study.European journal of medical research · 2026Article
- Atherogenic index of plasma is associated with poor prognosis in diabetic patients with acute kidney injury.Frontiers in endocrinology · 2026Article
- Cross-sectional association of the uric acid-to-HDL cholesterol ratio with diabetic kidney disease in patients with type 2 diabetes.Frontiers in nutrition · 2026Article
- High-density lipoprotein cholesterol and kidney disease progression in patients with type 2 diabetes mellitus: the Fukushima Cohort Study.BMJ open diabetes research & care · 2025Observational
- Article
- Multi-Omics Analysis and Nephroseq Database of Genes Related to Kidney Function in Diabetic Nephropathy Patients to Predict Potential Target Drugs.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Relationship Between Glycemic Indices and eGFR Values Among Type 2 Diabetes Mellitus Individuals With Chronic Kidney Disease Across Various Progression Stages.Clinical medicine insights. Endocrinology and diabetes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-density lipoprotein (HDL) exhibits multiple metabolic protective functions, such as facilitating cellular cholesterol efflux, antioxidant, anti-inflammatory, anti-apoptotic and anti-thrombotic properties, showing antidiabetic and renoprotective potential. Diabetic kidney disease (DKD) is considered to be associated with high-density lipoprotein cholesterol (HDL-C). The hyperglycemic environment, non-enzymatic glycosylation, carbamylation, oxidative stress and systemic inflammation can cause changes in the quantity and quality of HDL, resulting in reduced HDL levels and abnormal function. Dysfunctional HDL can also have a negative impact on pancreatic β cells and kidney cells, leading to the progression of DKD. Based on these findings, new HDL-related DKD risk predictors have gradually been proposed. Interventions aiming to improve HDL levels and function, such as infusion of recombinant HDL (rHDL) or lipid-poor apolipoprotein A-I (apoA-I), can significantly improve glycemic control and also show renal protective effects. However, recent studies have revealed a U-shaped relationship between HDL-C levels and DKD, and the loss of protective properties of high levels of HDL may be related to changes in composition and the deposition of dysfunctional particles that exacerbate damage. Further research is needed to fully elucidate the complex role of HDL in DKD. Given the important role of HDL in metabolic health, developing HDL-based therapies that augment HDL function, rather than simply increasing its level, is a critical step in managing the development and progression of DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.